Lanitop

Metildigoxin, the active ingredient in Lanitop, is a cardiac glycoside presented as an oral dosage form for systemic use. It is employed in the management of certain cardiac conditions, primarily in adult patients with heart failure or atrial arrhythmias. GNH USA supplies Lanitop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metildigoxin is used in cardiovascular therapy to modify cardiac contractility and rhythm. - Congestive heart failure: improves cardiac output and reduces symptoms of fluid overload. - Atrial fibrillation/flutter: helps control ventricular rate and maintains sinus rhythm. - Supraventricular tachycardia: assists in rate control when other measures are insufficient.

Metildigoxin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, especially after dose initiation. - Diarrhea: loose stools that may be transient. - Blurred vision: visual disturbances such as halos. - Fatigue: generalized tiredness or weakness. - Headache: mild cranial discomfort.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Severe bradycardia: markedly reduced heart rate requiring medical attention. - Heart block: conduction abnormalities that may need pacing. - Hyperkalemia: elevated serum potassium, especially in renal impairment. - Visual color changes: yellow‑green halos or reduced color perception. - Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.

Metildigoxin requires careful monitoring and specific safety measures. - Monitor serum electrolytes: especially potassium and magnesium levels. - Assess renal function: dose adjustment may be needed in impairment. - Check thyroid status: hypothyroidism can increase drug sensitivity. - Avoid use in patients with high‑grade AV block unless a pacemaker is present. - Store at room temperature: keep in the original container, protect from moisture and light.

Metildigoxin interacts with several medicines that can alter its plasma concentration or cardiac effects.

Major Interactions (Avoid): - Amiodarone: markedly increases Metildigoxin levels. - Quinidine: raises toxicity risk. - Verapamil: enhances negative chronotropic effect. - Spironolactone: elevates serum concentrations. - Macrolide antibiotics (e.g., erythromycin): increase risk of toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): may cause electrolyte shifts that predispose to toxicity. - ACE inhibitors: can affect potassium balance. - Beta‑blockers: additive bradycardia may occur.